Inovio Pharmaceuticals Inc (NYSEMKT:INO) gained 7.11% after the company announced that it will host a conference call and live webcast to report its first quarter 2014 financial results on Monday, May 12, 2014, at 8:30 a.m. ET. Management will discuss first quarter earnings and expectations for the current and upcoming quarters. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $2.45 moved to $2.48 on last trade day and at the end of the day closed at $2.40. Company price to sales ratio in past twelve months was calculated as 42.70 and price to cash ratio as 10.96. Inovio Pharmaceuticals Inc(NYSEMKT:INO) showed a positive weekly performance of 3.00%.
Cambrex Corp. (NYSE:CBM) posted its quarterly earnings results on Friday. The company reported $0.07 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.23 by $0.16, Analyst Ratings Network reports. The company had revenue of $66.20 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the prior year, the company posted $0.37 earnings per share. The company’s quarterly revenue was down 11.3% on a year-over-year basis. Cambrex Corp. updated its FY14 guidance to $0.99-1.10 EPS. Cambrex Corporation (NYSE:CBM) shares fell -5.30% in last trading session and ended the day on $18.21. CBM return on equity ratio is recorded as 13.90% and its return on assets is 5.80%. Cambrex Corporation (NYSE:CBM) yearly performance is 48.05%.
Biota Pharmaceuticals Inc (NASDAQ:BOTA) cratered -33.93% on Tuesday after the company revealed that a U.S. agency has asked the company to stop developing its experimental influenza drug, pending a decision related to the company’s contract with the agency.Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota Pharmaceuticals Inc(NASDAQ:BOTA) shares moved down -7.52% in last trading session and was closed at $3.32, while trading in range of $ 3.25 – 3.50. Biota Pharmaceuticals Inc (NASDAQ:BOTA) year to date (YTD) performance is -20.76%.
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will participate in the Sidoti Ninth Annual Micro-Cap Conference in New York City on May 9, 2014. Actinium Pharmaceuticals Inc(NYSEMKT:ATNM) weekly performance is -13.81%. On last trading day company shares ended up $10.30. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) distance from 50-day simple moving average (SMA50) is 6.63%. Analysts mean target price for the company is $18.00.
Biotech Losers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Cambrex Corporation (NYSE:CBM), Biota Pharmaceuticals (NASDAQ:BOTA), Actinium Pharmaceuticals (NYSEMKT:ATNM)